Cancer - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols AP2B1 and APC	Name 1 adaptor related protein complex 2 subunit beta 1	Name2 APC regulator of Wnt signaling pathway	Pathway 1 Nef Mediated CD4 Down-regulation Retrograde neurotrophin signalling Retrograde neurotrophin signalling Nef Mediated CD8 Down-regulation MHC class II antigen presentation EPH-ephrin mediated repulsion of cells Recycling pathway of L1 Recycling pathway of L1 WNT5A-dependent internalization of FZD4 WNT5A-dependent internalization of FZD2, FZD5 and ROR2 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis VLDLR internalisation and degradation LDL clearance Potential therapeutics for SARS	Pathway 2 Apoptotic cleavage of cellular proteins Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade Deactivation of the beta-catenin transactivating complex Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated APC truncation mutants are not K63 polyubiquitinated APC truncation mutants have impaired AXIN binding AXIN missense mutants destabilize the destruction complex Truncations of AMER1 destabilize the destruction complex Ovarian tumor domain proteases	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Cancer of the anal canal Familial adenomatous polyposis Gastric cancer Esophageal cancer Gallbladder cancer
Novel Novel	Symbols AQP1 and TMPRSS2	Name 1 aquaporin 1 (Colton blood group)	Name2 transmembrane serine protease 2	Pathway 1 Erythrocytes take up carbon dioxide and release oxygen Erythrocytes take up oxygen and release carbon dioxide Vasopressin regulates renal water homeostasis via Aquaporins Passive transport by Aquaporins Developmental Lineage of Pancreatic Ductal Cells	Pathway 2 Attachment and Entry Attachment and Entry Induction of Cell-Cell Fusion	Drugs 1 Acetazolamide B-nonylglucoside Mersalyl	Drugs 2 Bromhexine Camostat MM3122	Diseases 1	Diseases 2 Prostate cancer
Novel Novel	Symbols IRF4 and TRAF2	Name 1 interferon regulatory factor 4	Name2 TNF receptor associated factor 2	Pathway 1 Interleukin-4 and Interleukin-13 signaling Interferon gamma signaling Interferon alpha/beta signaling Nuclear events stimulated by ALK signaling in cancer Regulation of MITF-M-dependent genes involved in pigmentation	Pathway 2 Caspase activation via Death Receptors in the presence of ligand Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway TNFR2 non-canonical NF-kB pathway Regulation of necroptotic cell death TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway Ub-specific processing proteases Dimerization of procaspase-8 TNF signaling TRAF6 mediated IRF7 activation TRAF6 mediated NF-kB activation TRAF6 mediated NF-kB activation Defective RIPK1-mediated regulated necrosis Regulation of NF-kappa B signaling	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols HNRNPH1 and PCAT1	Name 1 heterogeneous nuclear ribonucleoprotein H1	Name2 prostate cancer associated transcript 1	Pathway 1 FGFR2 alternative splicing mRNA Splicing - Major Pathway Processing of Capped Intron-Containing Pre-mRNA	Pathway 2	Drugs 1 Copper	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols KRT31 and PRF1	Name 1 keratin 31	Name2 perforin 1	Pathway 1 Keratinization Formation of the cornified envelope	Pathway 2 Nuclear events stimulated by ALK signaling in cancer	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Familial hemophagocytic lymphohistiocytosis (FHPL), including the following three diseases: Perforin deficiency; Munc deficiency; STX11 deficiency
Novel Novel	Symbols AKT1 and AR	Name 1 AKT serine/threonine kinase 1	Name2 androgen receptor	Pathway 1 Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation MTOR signalling AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network eNOS activation AKT-mediated inactivation of FOXO1A Integrin signaling Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity Extra-nuclear estrogen signaling Negative regulation of NOTCH4 signaling FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Mitochondrial unfolded protein response (UPRmt) High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Mechanical load activates signaling by PIEZO1 and integrins in osteocytes	Pathway 2 HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 Ub-specific processing proteases RUNX2 regulates osteoblast differentiation RUNX2 regulates osteoblast differentiation	Drugs 1 ATP Arsenic trioxide Genistein Inositol 1,3,4,5-Tetrakisphosphate Resveratrol Archexin Enzastaurin Perifosine N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine	Drugs 2 Diethylstilbestrol Levonorgestrel Progesterone Spironolactone Flutamide Oxandrolone Fluphenazine Testosterone Mitotane Estrone Nilutamide Tamoxifen Norethisterone Drostanolone Norgestimate Nandrolone phenpropionate Ketoconazole Acetophenazine Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone propionate Oxybenzone 1-Testosterone Boldenone Calusterone Periciazine Prasterone Flufenamic acid Stanolone (R)-Bicalutamide Metribolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone acetate LGD2941 Dimethylcurcumin Oxymetholone Methyltestosterone Norelgestromin Stanozolol Tetrahydrogestrinone (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide BMS-564929 S-23 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide Andarine (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile LGD-2226 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Triclosan Nandrolone decanoate Ulipristal Enzalutamide Eugenol Dienogest Norethynodrel Norgestrel Homosalate Enzacamene Luprostiol Mibolerone Phenothiazine Gestrinone Apalutamide Clascoterone Darolutamide Esculin Ligandrol Testosterone cypionate Testosterone enanthate Testosterone undecanoate Stanolone acetate Segesterone acetate Boldenone undecylenate Echinacoside Ketodarolutamide	Diseases 1 PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome	Diseases 2 Spinal and bulbar muscular atrophy (SBMA); Kennedy's disease 46,XY disorders of sex development (Other), including: Persistent Mullerian duct syndrome; Hypospadias; Cryptorchidism Prostate cancer 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
Novel Novel	Symbols MRE11 and NKX3-1	Name 1 MRE11 double strand break repair nuclease	Name2 NK3 homeobox 1	Pathway 1 Cytosolic sensors of pathogen-associated DNA DNA Damage/Telomere Stress Induced Senescence IRF3-mediated induction of type I IFN HDR through Single Strand Annealing (SSA) HDR through MMEJ (alt-NHEJ) HDR through Homologous Recombination (HRR) Sensing of DNA Double Strand Breaks Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Resolution of D-loop Structures through Holliday Junction Intermediates Nonhomologous End-Joining (NHEJ) Homologous DNA Pairing and Strand Exchange Processing of DNA double-strand break ends Presynaptic phase of homologous DNA pairing and strand exchange Regulation of TP53 Activity through Phosphorylation G2/M DNA damage checkpoint Meiotic recombination Defective homologous recombination repair (HRR) due to BRCA1 loss of function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function Impaired BRCA2 binding to RAD51 Impaired BRCA2 binding to PALB2	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Ataxia with ocular apraxia (AOA), including: Ataxia telangiectasia (AT); Ataxia telangiectasia like disorder (ATLD); Ataxia oculomotor apraxia type 1 (AOA1); Ataxia oculomotor apraxia type 2 (AOA2) DNA repair defects, including the following six diseases: Ataxia telangiectasia (AT); Ataxia-talangiectasia-like syndrome; Nijmegen syndrome; DNA ligase I deficiency; DNA ligase IV deficiency; Bloom's syndrome	Diseases 2
Novel Novel	Symbols EGF and EGFR	Name 1 epidermal growth factor	Name2 epidermal growth factor receptor	Pathway 1 Platelet degranulation Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma Constitutive Signaling by Aberrant PI3K in Cancer Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Downregulation of ERBB2 signaling Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin NFE2L2 regulating tumorigenic genes Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Multipotent Pancreatic Progenitor Cells	Pathway 2 Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Respiratory syncytial virus (RSV) attachment and entry Developmental Lineage of Mammary Gland Myoepithelial Cells	Drugs 1 Sucralfate Alpha-Aminobutyric Acid Cholecystokinin Tesevatinib Oleandrin	Drugs 2 Cetuximab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib AV-412 S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE PD-168393 Afatinib Osimertinib Necitumumab Foreskin keratinocyte (neonatal) Depatuxizumab mafodotin Icotinib Neratinib Dacomitinib Fostamatinib Poziotinib Zalutumumab Brigatinib Olmutinib Zanubrutinib Abivertinib Mobocertinib Almonertinib Amivantamab	Diseases 1 Gastric cancer	Diseases 2 Laryngeal cancer Cervical cancer Oral cancer Gastric cancer Choriocarcinoma Esophageal cancer Glioma Bladder cancer
Novel Novel	Symbols HLA-DMB and HLA-DRA	Name 1 major histocompatibility complex, class II, DM beta	Name2 major histocompatibility complex, class II, DR alpha	Pathway 1 MHC class II antigen presentation	Pathway 2 Downstream TCR signaling Phosphorylation of CD3 and TCR zeta chains Translocation of ZAP-70 to Immunological synapse Generation of second messenger molecules MHC class II antigen presentation Co-inhibition by PD-1 Interferon gamma signaling	Drugs 1	Drugs 2 1D09C3 Coccidioides immitis spherule	Diseases 1	Diseases 2
Novel Novel	Symbols CD80 and CTLA4	Name 1 CD80 molecule	Name2 cytotoxic T-lymphocyte associated protein 4	Pathway 1 PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Co-stimulation by CD28 CD28 dependent PI3K/Akt signaling CD28 dependent Vav1 pathway Co-inhibition by CTLA4 Interleukin-10 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Pathway 2 Co-stimulation by CD28 Co-inhibition by CTLA4 RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)	Drugs 1 Abatacept Galiximab Belatacept	Drugs 2 Abatacept Ipilimumab Tremelimumab	Diseases 1	Diseases 2 Graves' disease Allograft rejection Type I diabetes mellitus Hashimoto's thyroiditis
Novel Novel	Symbols FGFR4 and FGF19	Name 1 fibroblast growth factor receptor 4	Name2 fibroblast growth factor 19	Pathway 1 PI3K Cascade PIP3 activates AKT signaling betaKlotho-mediated ligand binding FGFR4 mutant receptor activation FGFR4 ligand binding and activation Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade; FGFR4 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR4 signaling Signaling by FGFR4 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Pathway 2 PI3K Cascade PIP3 activates AKT signaling betaKlotho-mediated ligand binding FGFR4 ligand binding and activation Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade; FGFR4 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR4 signaling RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Drugs 1 Heparin Ponatinib Lenvatinib Infigratinib Erdafitinib Pemigatinib Futibatinib	Drugs 2 Heparin	Diseases 1	Diseases 2
Novel Novel	Symbols C2 and C4B	Name 1 complement C2	Name2 complement C4B (Chido/Rodgers blood group)	Pathway 1 Initial triggering of complement Activation of C3 and C5 Regulation of Complement cascade	Pathway 2 Initial triggering of complement Activation of C3 and C5 Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation Regulation of Complement cascade Initial triggering of complement Activation of C3 and C5 Regulation of Complement cascade	Drugs 1	Drugs 2 Human immunoglobulin G Human immunoglobulin G Zinc Copper Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Diseases 1 Systemic lupus erythematosus Classic complement pathway component defects, including the following eight diseases: C1q alpha-chain deficiency; C1q beta-chain deficiency; C1q gamma-chain deficiency; C1r deficiency; C1s deficiency; C2 deficiency; C3 deficiency; C4 deficiency	Diseases 2
Novel Novel	Symbols FGF3 and EBNA1BP2	Name 1 fibroblast growth factor 3	Name2 EBNA1 binding protein 2	Pathway 1 PI3K Cascade PIP3 activates AKT signaling FGFR1b ligand binding and activation FGFR2b ligand binding and activation Activated point mutants of FGFR2 Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Signaling by FGFR2 in disease FGFRL1 modulation of FGFR1 signaling RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Pathway 2 Major pathway of rRNA processing in the nucleolus and cytosol	Drugs 1	Drugs 2	Diseases 1 Kaposi's sarcoma	Diseases 2
Novel Novel	Symbols FGF10 and FGFR2	Name 1 fibroblast growth factor 10	Name2 fibroblast growth factor receptor 2	Pathway 1 PI3K Cascade PIP3 activates AKT signaling FGFR1b ligand binding and activation FGFR2b ligand binding and activation Activated point mutants of FGFR2 Regulation of gene expression in early pancreatic precursor cells Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Signaling by FGFR2 in disease FGFRL1 modulation of FGFR1 signaling RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Developmental Lineage of Multipotent Pancreatic Progenitor Cells Developmental Lineage of Mammary Stem Cells	Pathway 2 Signaling by FGFR2 amplification mutants Activated point mutants of FGFR2 Signaling by FGFR2 in disease Signaling by FGFR2 IIIa TM Signaling by FGFR2 fusions	Drugs 1	Drugs 2 Palifermin Heparin Sucrosofate 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine Regorafenib Ponatinib Lenvatinib Nintedanib Foreskin fibroblast (neonatal) Foreskin keratinocyte (neonatal) Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib Pralsetinib	Diseases 1 Aplasia of lacrimal and salivary glands Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome	Diseases 2 Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome Gastric cancer Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
Novel Novel	Symbols CTAG1B and CTAG1A	Name 1 cancer/testis antigen 1B	Name2 cancer/testis antigen 1A	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FGF6 and FGFR1	Name 1 fibroblast growth factor 6	Name2 fibroblast growth factor receptor 1	Pathway 1 PI3K Cascade PIP3 activates AKT signaling Signaling by activated point mutants of FGFR1 FGFR4 ligand binding and activation FGFR1c ligand binding and activation FGFR2c ligand binding and activation Activated point mutants of FGFR2 Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Phospholipase C-mediated cascade; FGFR4 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR4 signaling Signaling by FGFR2 in disease Signaling by FGFR1 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Pathway 2 Signaling by activated point mutants of FGFR1 Signaling by FGFR1 in disease Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm	Drugs 1	Drugs 2 Palifermin Sorafenib Heparin 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone XL999 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE Regorafenib Ponatinib Lenvatinib Nintedanib Tivozanib Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib Pralsetinib	Diseases 1	Diseases 2 Hypogonadotropic hypogonadism; Kallmann syndrome (KAL) Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD) Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
Novel Novel	Symbols FGF4 and FGFR1	Name 1 fibroblast growth factor 4	Name2 fibroblast growth factor receptor 1	Pathway 1 PI3K Cascade PIP3 activates AKT signaling Signaling by activated point mutants of FGFR1 Signaling by activated point mutants of FGFR3 FGFR4 ligand binding and activation FGFR3c ligand binding and activation FGFR1c ligand binding and activation FGFR2c ligand binding and activation Activated point mutants of FGFR2 Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Phospholipase C-mediated cascade; FGFR3 Phospholipase C-mediated cascade; FGFR4 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Signaling by FGFR2 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease FGFRL1 modulation of FGFR1 signaling RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Specification of the neural plate border Developmental Lineage of Multipotent Pancreatic Progenitor Cells	Pathway 2 Signaling by activated point mutants of FGFR1 Signaling by FGFR1 in disease Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm	Drugs 1 Pentosan polysulfate Heparin TP-508	Drugs 2 Palifermin Sorafenib Heparin 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone XL999 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE Regorafenib Ponatinib Lenvatinib Nintedanib Tivozanib Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib Pralsetinib	Diseases 1	Diseases 2 Hypogonadotropic hypogonadism; Kallmann syndrome (KAL) Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD) Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
Novel Novel	Symbols CT45A1 and CT45A10	Name 1 cancer/testis antigen family 45 member A1	Name2 cancer/testis antigen family 45 member A10	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FLNC and WNK1	Name 1 filamin C	Name2 WNK lysine deficient protein kinase 1	Pathway 1 Cell-extracellular matrix interactions	Pathway 2 Stimuli-sensing channels	Drugs 1	Drugs 2	Diseases 1 Myofibrillar myopathies (MFM), including: Desminopathy (MFM1); alpha-B Crystallinopathy (MFM2); Myotilinopathy (MFM3); Zaspopathy (MFM4); Filaminopathy (MFM5); Bag3opathy	Diseases 2 Hyperkalemic distal renal tubular acidosis (RTA type 4), including the following two diseases: Pseudohypoaldosteronism type I (PHA1); Pseudohypoaldosteronism type II (Gordon's syndrome)
Novel Novel	Symbols FLNC and SYNPO2	Name 1 filamin C	Name2 synaptopodin 2	Pathway 1 Cell-extracellular matrix interactions	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Myofibrillar myopathies (MFM), including: Desminopathy (MFM1); alpha-B Crystallinopathy (MFM2); Myotilinopathy (MFM3); Zaspopathy (MFM4); Filaminopathy (MFM5); Bag3opathy	Diseases 2
Novel	Symbols AP2B1 and APC	Name 1 adaptor related protein complex 2 subunit beta 1	Name2 APC regulator of Wnt signaling pathway	Pathway 1 Nef Mediated CD4 Down-regulation Retrograde neurotrophin signalling Retrograde neurotrophin signalling Nef Mediated CD8 Down-regulation MHC class II antigen presentation EPH-ephrin mediated repulsion of cells Recycling pathway of L1 Recycling pathway of L1 WNT5A-dependent internalization of FZD4 WNT5A-dependent internalization of FZD2, FZD5 and ROR2 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis VLDLR internalisation and degradation LDL clearance Potential therapeutics for SARS	Pathway 2 Apoptotic cleavage of cellular proteins Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade Deactivation of the beta-catenin transactivating complex Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated APC truncation mutants are not K63 polyubiquitinated APC truncation mutants have impaired AXIN binding AXIN missense mutants destabilize the destruction complex Truncations of AMER1 destabilize the destruction complex Ovarian tumor domain proteases	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Cancer of the anal canal Familial adenomatous polyposis Gastric cancer Esophageal cancer Gallbladder cancer
Novel	Symbols AQP1 and TMPRSS2	Name 1 aquaporin 1 (Colton blood group)	Name2 transmembrane serine protease 2	Pathway 1 Erythrocytes take up carbon dioxide and release oxygen Erythrocytes take up oxygen and release carbon dioxide Vasopressin regulates renal water homeostasis via Aquaporins Passive transport by Aquaporins Developmental Lineage of Pancreatic Ductal Cells	Pathway 2 Attachment and Entry Attachment and Entry Induction of Cell-Cell Fusion	Drugs 1 Acetazolamide B-nonylglucoside Mersalyl	Drugs 2 Bromhexine Camostat MM3122	Diseases 1	Diseases 2 Prostate cancer
Novel	Symbols IRF4 and TRAF2	Name 1 interferon regulatory factor 4	Name2 TNF receptor associated factor 2	Pathway 1 Interleukin-4 and Interleukin-13 signaling Interferon gamma signaling Interferon alpha/beta signaling Nuclear events stimulated by ALK signaling in cancer Regulation of MITF-M-dependent genes involved in pigmentation	Pathway 2 Caspase activation via Death Receptors in the presence of ligand Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway TNFR2 non-canonical NF-kB pathway Regulation of necroptotic cell death TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway Ub-specific processing proteases Dimerization of procaspase-8 TNF signaling TRAF6 mediated IRF7 activation TRAF6 mediated NF-kB activation TRAF6 mediated NF-kB activation Defective RIPK1-mediated regulated necrosis Regulation of NF-kappa B signaling	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols HNRNPH1 and PCAT1	Name 1 heterogeneous nuclear ribonucleoprotein H1	Name2 prostate cancer associated transcript 1	Pathway 1 FGFR2 alternative splicing mRNA Splicing - Major Pathway Processing of Capped Intron-Containing Pre-mRNA	Pathway 2	Drugs 1 Copper	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols KRT31 and PRF1	Name 1 keratin 31	Name2 perforin 1	Pathway 1 Keratinization Formation of the cornified envelope	Pathway 2 Nuclear events stimulated by ALK signaling in cancer	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Familial hemophagocytic lymphohistiocytosis (FHPL), including the following three diseases: Perforin deficiency; Munc deficiency; STX11 deficiency
Novel	Symbols AKT1 and AR	Name 1 AKT serine/threonine kinase 1	Name2 androgen receptor	Pathway 1 Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation MTOR signalling AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network eNOS activation AKT-mediated inactivation of FOXO1A Integrin signaling Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity Extra-nuclear estrogen signaling Negative regulation of NOTCH4 signaling FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Mitochondrial unfolded protein response (UPRmt) High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Mechanical load activates signaling by PIEZO1 and integrins in osteocytes	Pathway 2 HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 Ub-specific processing proteases RUNX2 regulates osteoblast differentiation RUNX2 regulates osteoblast differentiation	Drugs 1 ATP Arsenic trioxide Genistein Inositol 1,3,4,5-Tetrakisphosphate Resveratrol Archexin Enzastaurin Perifosine N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine	Drugs 2 Diethylstilbestrol Levonorgestrel Progesterone Spironolactone Flutamide Oxandrolone Fluphenazine Testosterone Mitotane Estrone Nilutamide Tamoxifen Norethisterone Drostanolone Norgestimate Nandrolone phenpropionate Ketoconazole Acetophenazine Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone propionate Oxybenzone 1-Testosterone Boldenone Calusterone Periciazine Prasterone Flufenamic acid Stanolone (R)-Bicalutamide Metribolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone acetate LGD2941 Dimethylcurcumin Oxymetholone Methyltestosterone Norelgestromin Stanozolol Tetrahydrogestrinone (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide BMS-564929 S-23 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide Andarine (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile LGD-2226 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Triclosan Nandrolone decanoate Ulipristal Enzalutamide Eugenol Dienogest Norethynodrel Norgestrel Homosalate Enzacamene Luprostiol Mibolerone Phenothiazine Gestrinone Apalutamide Clascoterone Darolutamide Esculin Ligandrol Testosterone cypionate Testosterone enanthate Testosterone undecanoate Stanolone acetate Segesterone acetate Boldenone undecylenate Echinacoside Ketodarolutamide	Diseases 1 PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome	Diseases 2 Spinal and bulbar muscular atrophy (SBMA); Kennedy's disease 46,XY disorders of sex development (Other), including: Persistent Mullerian duct syndrome; Hypospadias; Cryptorchidism Prostate cancer 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
Novel	Symbols MRE11 and NKX3-1	Name 1 MRE11 double strand break repair nuclease	Name2 NK3 homeobox 1	Pathway 1 Cytosolic sensors of pathogen-associated DNA DNA Damage/Telomere Stress Induced Senescence IRF3-mediated induction of type I IFN HDR through Single Strand Annealing (SSA) HDR through MMEJ (alt-NHEJ) HDR through Homologous Recombination (HRR) Sensing of DNA Double Strand Breaks Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Resolution of D-loop Structures through Holliday Junction Intermediates Nonhomologous End-Joining (NHEJ) Homologous DNA Pairing and Strand Exchange Processing of DNA double-strand break ends Presynaptic phase of homologous DNA pairing and strand exchange Regulation of TP53 Activity through Phosphorylation G2/M DNA damage checkpoint Meiotic recombination Defective homologous recombination repair (HRR) due to BRCA1 loss of function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function Impaired BRCA2 binding to RAD51 Impaired BRCA2 binding to PALB2	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Ataxia with ocular apraxia (AOA), including: Ataxia telangiectasia (AT); Ataxia telangiectasia like disorder (ATLD); Ataxia oculomotor apraxia type 1 (AOA1); Ataxia oculomotor apraxia type 2 (AOA2) DNA repair defects, including the following six diseases: Ataxia telangiectasia (AT); Ataxia-talangiectasia-like syndrome; Nijmegen syndrome; DNA ligase I deficiency; DNA ligase IV deficiency; Bloom's syndrome	Diseases 2
Novel	Symbols EGF and EGFR	Name 1 epidermal growth factor	Name2 epidermal growth factor receptor	Pathway 1 Platelet degranulation Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma Constitutive Signaling by Aberrant PI3K in Cancer Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Downregulation of ERBB2 signaling Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin NFE2L2 regulating tumorigenic genes Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Multipotent Pancreatic Progenitor Cells	Pathway 2 Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Respiratory syncytial virus (RSV) attachment and entry Developmental Lineage of Mammary Gland Myoepithelial Cells	Drugs 1 Sucralfate Alpha-Aminobutyric Acid Cholecystokinin Tesevatinib Oleandrin	Drugs 2 Cetuximab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib AV-412 S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE PD-168393 Afatinib Osimertinib Necitumumab Foreskin keratinocyte (neonatal) Depatuxizumab mafodotin Icotinib Neratinib Dacomitinib Fostamatinib Poziotinib Zalutumumab Brigatinib Olmutinib Zanubrutinib Abivertinib Mobocertinib Almonertinib Amivantamab	Diseases 1 Gastric cancer	Diseases 2 Laryngeal cancer Cervical cancer Oral cancer Gastric cancer Choriocarcinoma Esophageal cancer Glioma Bladder cancer
Novel	Symbols HLA-DMB and HLA-DRA	Name 1 major histocompatibility complex, class II, DM beta	Name2 major histocompatibility complex, class II, DR alpha	Pathway 1 MHC class II antigen presentation	Pathway 2 Downstream TCR signaling Phosphorylation of CD3 and TCR zeta chains Translocation of ZAP-70 to Immunological synapse Generation of second messenger molecules MHC class II antigen presentation Co-inhibition by PD-1 Interferon gamma signaling	Drugs 1	Drugs 2 1D09C3 Coccidioides immitis spherule	Diseases 1	Diseases 2
Novel	Symbols CD80 and CTLA4	Name 1 CD80 molecule	Name2 cytotoxic T-lymphocyte associated protein 4	Pathway 1 PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Co-stimulation by CD28 CD28 dependent PI3K/Akt signaling CD28 dependent Vav1 pathway Co-inhibition by CTLA4 Interleukin-10 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Pathway 2 Co-stimulation by CD28 Co-inhibition by CTLA4 RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)	Drugs 1 Abatacept Galiximab Belatacept	Drugs 2 Abatacept Ipilimumab Tremelimumab	Diseases 1	Diseases 2 Graves' disease Allograft rejection Type I diabetes mellitus Hashimoto's thyroiditis
Novel	Symbols FGFR4 and FGF19	Name 1 fibroblast growth factor receptor 4	Name2 fibroblast growth factor 19	Pathway 1 PI3K Cascade PIP3 activates AKT signaling betaKlotho-mediated ligand binding FGFR4 mutant receptor activation FGFR4 ligand binding and activation Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade; FGFR4 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR4 signaling Signaling by FGFR4 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Pathway 2 PI3K Cascade PIP3 activates AKT signaling betaKlotho-mediated ligand binding FGFR4 ligand binding and activation Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade; FGFR4 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR4 signaling RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Drugs 1 Heparin Ponatinib Lenvatinib Infigratinib Erdafitinib Pemigatinib Futibatinib	Drugs 2 Heparin	Diseases 1	Diseases 2
Novel	Symbols C2 and C4B	Name 1 complement C2	Name2 complement C4B (Chido/Rodgers blood group)	Pathway 1 Initial triggering of complement Activation of C3 and C5 Regulation of Complement cascade	Pathway 2 Initial triggering of complement Activation of C3 and C5 Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation Regulation of Complement cascade Initial triggering of complement Activation of C3 and C5 Regulation of Complement cascade	Drugs 1	Drugs 2 Human immunoglobulin G Human immunoglobulin G Zinc Copper Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Diseases 1 Systemic lupus erythematosus Classic complement pathway component defects, including the following eight diseases: C1q alpha-chain deficiency; C1q beta-chain deficiency; C1q gamma-chain deficiency; C1r deficiency; C1s deficiency; C2 deficiency; C3 deficiency; C4 deficiency	Diseases 2
Novel	Symbols FGF3 and EBNA1BP2	Name 1 fibroblast growth factor 3	Name2 EBNA1 binding protein 2	Pathway 1 PI3K Cascade PIP3 activates AKT signaling FGFR1b ligand binding and activation FGFR2b ligand binding and activation Activated point mutants of FGFR2 Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Signaling by FGFR2 in disease FGFRL1 modulation of FGFR1 signaling RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Pathway 2 Major pathway of rRNA processing in the nucleolus and cytosol	Drugs 1	Drugs 2	Diseases 1 Kaposi's sarcoma	Diseases 2
Novel	Symbols FGF10 and FGFR2	Name 1 fibroblast growth factor 10	Name2 fibroblast growth factor receptor 2	Pathway 1 PI3K Cascade PIP3 activates AKT signaling FGFR1b ligand binding and activation FGFR2b ligand binding and activation Activated point mutants of FGFR2 Regulation of gene expression in early pancreatic precursor cells Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Signaling by FGFR2 in disease FGFRL1 modulation of FGFR1 signaling RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Developmental Lineage of Multipotent Pancreatic Progenitor Cells Developmental Lineage of Mammary Stem Cells	Pathway 2 Signaling by FGFR2 amplification mutants Activated point mutants of FGFR2 Signaling by FGFR2 in disease Signaling by FGFR2 IIIa TM Signaling by FGFR2 fusions	Drugs 1	Drugs 2 Palifermin Heparin Sucrosofate 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine Regorafenib Ponatinib Lenvatinib Nintedanib Foreskin fibroblast (neonatal) Foreskin keratinocyte (neonatal) Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib Pralsetinib	Diseases 1 Aplasia of lacrimal and salivary glands Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome	Diseases 2 Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome Gastric cancer Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
Novel	Symbols CTAG1B and CTAG1A	Name 1 cancer/testis antigen 1B	Name2 cancer/testis antigen 1A	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FGF6 and FGFR1	Name 1 fibroblast growth factor 6	Name2 fibroblast growth factor receptor 1	Pathway 1 PI3K Cascade PIP3 activates AKT signaling Signaling by activated point mutants of FGFR1 FGFR4 ligand binding and activation FGFR1c ligand binding and activation FGFR2c ligand binding and activation Activated point mutants of FGFR2 Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Phospholipase C-mediated cascade; FGFR4 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR4 signaling Signaling by FGFR2 in disease Signaling by FGFR1 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Pathway 2 Signaling by activated point mutants of FGFR1 Signaling by FGFR1 in disease Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm	Drugs 1	Drugs 2 Palifermin Sorafenib Heparin 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone XL999 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE Regorafenib Ponatinib Lenvatinib Nintedanib Tivozanib Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib Pralsetinib	Diseases 1	Diseases 2 Hypogonadotropic hypogonadism; Kallmann syndrome (KAL) Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD) Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
Novel	Symbols FGF4 and FGFR1	Name 1 fibroblast growth factor 4	Name2 fibroblast growth factor receptor 1	Pathway 1 PI3K Cascade PIP3 activates AKT signaling Signaling by activated point mutants of FGFR1 Signaling by activated point mutants of FGFR3 FGFR4 ligand binding and activation FGFR3c ligand binding and activation FGFR1c ligand binding and activation FGFR2c ligand binding and activation Activated point mutants of FGFR2 Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Phospholipase C-mediated cascade; FGFR3 Phospholipase C-mediated cascade; FGFR4 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Signaling by FGFR2 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease FGFRL1 modulation of FGFR1 signaling RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Specification of the neural plate border Developmental Lineage of Multipotent Pancreatic Progenitor Cells	Pathway 2 Signaling by activated point mutants of FGFR1 Signaling by FGFR1 in disease Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm	Drugs 1 Pentosan polysulfate Heparin TP-508	Drugs 2 Palifermin Sorafenib Heparin 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone XL999 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE Regorafenib Ponatinib Lenvatinib Nintedanib Tivozanib Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib Pralsetinib	Diseases 1	Diseases 2 Hypogonadotropic hypogonadism; Kallmann syndrome (KAL) Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD) Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
Novel	Symbols CT45A1 and CT45A10	Name 1 cancer/testis antigen family 45 member A1	Name2 cancer/testis antigen family 45 member A10	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FLNC and WNK1	Name 1 filamin C	Name2 WNK lysine deficient protein kinase 1	Pathway 1 Cell-extracellular matrix interactions	Pathway 2 Stimuli-sensing channels	Drugs 1	Drugs 2	Diseases 1 Myofibrillar myopathies (MFM), including: Desminopathy (MFM1); alpha-B Crystallinopathy (MFM2); Myotilinopathy (MFM3); Zaspopathy (MFM4); Filaminopathy (MFM5); Bag3opathy	Diseases 2 Hyperkalemic distal renal tubular acidosis (RTA type 4), including the following two diseases: Pseudohypoaldosteronism type I (PHA1); Pseudohypoaldosteronism type II (Gordon's syndrome)
Novel	Symbols FLNC and SYNPO2	Name 1 filamin C	Name2 synaptopodin 2	Pathway 1 Cell-extracellular matrix interactions	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Myofibrillar myopathies (MFM), including: Desminopathy (MFM1); alpha-B Crystallinopathy (MFM2); Myotilinopathy (MFM3); Zaspopathy (MFM4); Filaminopathy (MFM5); Bag3opathy	Diseases 2

Page 9 out of 98 pages

Search Results : Cancer